Celltrion, Inc. (068270.KS)

183.400,00 -2.400,00 (-1,29%) Börsenschluss: 03:30PM KST

Celltrion, Inc.

23 Academy-ro
Yeonsu-gu
Incheon
South Korea
82 3 2850 5000
https://www.celltrion.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Hyong-Gi Kim	CEO & Internal Director	N/A	N/A	1965
Mr. Woo-Sung Kee	CEO & Internal Director	N/A	N/A	1961
Jin-seok Seo	Co-CEO & Inside Co-Chairman of the Board	N/A	N/A	N/A
Mr. Stephen Yeum	Founder	N/A	N/A	N/A
Mr. Min-Cheol Shin	Director of Finance	N/A	N/A	1971
Mr. Ji-Hoon Choi	Director of Legal Affairs	N/A	N/A	1971

Die Beträge haben den Stand 31. Dezember 2011 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in KRW.

Beschreibung

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Corporate Governance

Celltrion, Inc.s ISS Governance QualityScore, Stand 1. Juli 2024, lautet 3. Die grundlegenden Scores sind Audit: 1, Vorstand: 3, Shareholderrechte: 3, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.